Overview
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications. Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers. Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than tiotropium. Glycopyrronium was originally granted FDA approval on 11 August 1961.
Indication
Glycopyrronium formulated as a topical cloth is indicated to treat primary axillary hyperhidrosis in patients ≥9 years, and an inhalational solution is indicated for long term maintenance of airflow obstruction in COPD. A glycopyrronium intravenous and intramuscular injection is indicated in adults and pediatric patients to reduce the volume and acidity of gastric secretions, reduce airway secretions, and block cardiac inhibitory reflexes during the induction of anesthesia and intubation; to treat surgically-induced, drug-induced, or vagal reflex associated arrhythmias intraoperatively; and to prevent peripheral muscarinic effects of cholinergic drugs. The same injection is indicated in adults as an adjunct therapy in the treatment of peptic ulcers, as is an orally disintegrating tablet formulation. An oral solution is indicated to treat excessive drooling associated with neurologic conditions in patients aged 3-16 years. Glycopyrronium and budesonide can be formulated with formoterol fumarate for the maintenance of COPD.
Associated Conditions
- Airway Obstruction
- Chronic Obstructive Pulmonary Disease (COPD)
- Increased upper airway secretion
- Peptic Ulcer
- Primary Axillary Hyperhidrosis
- Sialorrhea
- Cardiac vagal inhibitory reflexes
- Cardiac vagal inhibitory reflexes caused by General Surgery
- Cardiac vagal inhibitory reflexes caused by Medication
- Gastric secretions
- Peripheral muscarinic effects
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2017/03/21 | Phase 2 | Completed | |||
2017/03/16 | Phase 4 | Completed | |||
2017/02/10 | Not Applicable | Completed | Eunah Cho, MD | ||
2017/01/31 | Phase 1 | Completed | |||
2016/11/02 | Phase 4 | Completed | |||
2016/11/01 | Phase 2 | Completed | Sunovion Respiratory Development Inc. | ||
2016/10/28 | Phase 2 | Completed | Sunovion Respiratory Development Inc. | ||
2016/08/19 | Phase 4 | Terminated | Kokila N Thenuwara | ||
2016/08/18 | Phase 4 | Completed | |||
2016/08/09 | Phase 4 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 63323-578 | INTRAMUSCULAR, INTRAVENOUS | 0.2 mg in 1 mL | 8/16/2023 | |
| Par Pharmaceutical, Inc. | 49884-065 | ORAL | 1 mg in 1 1 | 12/13/2018 | |
| Par Pharmaceutical, Inc. | 49884-066 | ORAL | 2 mg in 1 1 | 12/13/2018 | |
| Taro Pharmaceuticals U.S.A. Inc. | 51672-5316 | ORAL | 1 mg in 5 mL | 1/9/2024 | |
| Meitheal Pharmaceuticals Inc. | 71288-415 | INTRAVENOUS, INTRAMUSCULAR | 0.2 mg in 1 mL | 7/6/2021 | |
| Medical Purchasing Solutions, LLC | 71872-7181 | INTRAMUSCULAR, INTRAVENOUS | 0.2 mg in 1 mL | 5/11/2023 | |
| Bryant Ranch Prepack | 72162-1477 | ORAL | 1 mg in 1 1 | 12/13/2018 | |
| Exela Pharma Sciences, LLC | 51754-6001 | INTRAMUSCULAR, INTRAVENOUS | 0.2 mg in 1 mL | 8/1/2018 | |
| Bryant Ranch Prepack | 71335-2075 | ORAL | 1 mg in 1 1 | 3/10/2022 | |
| Edenbridge Pharmaceuticals LLC. | 82111-518 | ORAL | 1.7 mg in 1 1 | 10/24/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.